Alder BioPharmaceuticals (ALDR) vs. Its Rivals Head to Head Analysis
Alder BioPharmaceuticals (NASDAQ: ALDR) is one of 283 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Alder BioPharmaceuticals to related companies based on the strength of its institutional ownership, profitability, risk, valuation, analyst recommendations, earnings and dividends.
This table compares Alder BioPharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Alder BioPharmaceuticals Competitors||-5,335.58%||-469.25%||-39.69%|
Earnings & Valuation
This table compares Alder BioPharmaceuticals and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Alder BioPharmaceuticals||$110,000.00||-$156.25 million||-1.98|
|Alder BioPharmaceuticals Competitors||$286.20 million||$34.74 million||145.50|
Alder BioPharmaceuticals’ peers have higher revenue and earnings than Alder BioPharmaceuticals. Alder BioPharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
78.9% of Alder BioPharmaceuticals shares are held by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 10.6% of Alder BioPharmaceuticals shares are held by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a summary of current recommendations for Alder BioPharmaceuticals and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Alder BioPharmaceuticals Competitors||804||3164||11461||230||2.71|
Alder BioPharmaceuticals presently has a consensus target price of $30.58, indicating a potential upside of 188.52%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.69%. Given Alder BioPharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Alder BioPharmaceuticals is more favorable than its peers.
Risk and Volatility
Alder BioPharmaceuticals has a beta of 2.55, suggesting that its stock price is 155% more volatile than the S&P 500. Comparatively, Alder BioPharmaceuticals’ peers have a beta of 6.09, suggesting that their average stock price is 509% more volatile than the S&P 500.
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder’s third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.
Receive News & Stock Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.